Amedisys Inc (NASDAQ:AMED) insider Denise M. Bohnert sold 362 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $220.00, for a total transaction of $79,640.00. Following the completion of the transaction, the insider now owns 9,095 shares of the company’s stock, valued at approximately $2,000,900. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Amedisys stock opened at $234.16 on Friday. Amedisys Inc has a 12-month low of $121.00 and a 12-month high of $237.28. The stock has a market capitalization of $7.58 billion, a P/E ratio of 60.66, a P/E/G ratio of 3.44 and a beta of 0.95. The firm’s 50-day moving average is $202.10 and its two-hundred day moving average is $187.33. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.02 and a quick ratio of 1.48.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, July 28th. The health services provider reported $1.34 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.53. Amedisys had a net margin of 6.50% and a return on equity of 22.41%. The company had revenue of $485.06 million for the quarter, compared to analysts’ expectations of $468.38 million. During the same period last year, the company earned $1.21 EPS. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, analysts forecast that Amedisys Inc will post 4.82 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in AMED. FMR LLC boosted its stake in shares of Amedisys by 13.4% during the 1st quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock worth $45,703,000 after purchasing an additional 43,844 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Amedisys by 18.8% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,828 shares of the health services provider’s stock worth $444,000 after acquiring an additional 448 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Amedisys by 3.9% in the fourth quarter. Geode Capital Management LLC now owns 469,777 shares of the health services provider’s stock worth $78,415,000 after acquiring an additional 17,435 shares during the last quarter. Sunbelt Securities Inc. acquired a new stake in shares of Amedisys in the fourth quarter worth approximately $9,222,000. Finally, Macquarie Group Ltd. boosted its position in shares of Amedisys by 64.7% in the fourth quarter. Macquarie Group Ltd. now owns 24,386 shares of the health services provider’s stock worth $4,070,000 after acquiring an additional 9,582 shares during the last quarter. 88.31% of the stock is currently owned by institutional investors.

A number of equities analysts have recently issued reports on the stock. BidaskClub upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Jefferies Financial Group increased their price target on shares of Amedisys from $225.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday. UBS Group cut their price target on shares of Amedisys from $208.00 to $190.00 and set a “neutral” rating for the company in a report on Monday, May 11th. Royal Bank of Canada increased their price target on shares of Amedisys from $218.00 to $260.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Oppenheimer reiterated a “buy” rating and issued a $215.00 price target on shares of Amedisys in a report on Monday, April 27th. Five equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Amedisys has a consensus rating of “Buy” and a consensus price target of $215.67.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Further Reading: Sell-Side Analysts

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.